Dietary Nucleotides and Ribose on Muscle Fuel Utilisation (FUN)

The Effect of Dietary Nucleotides and Ribose on Muscle Fuel Utilisation and Exercise Performance

Nucleotides are the building blocks for a variety of molecules, including ATP, which is broken down in the skeletal muscle cells to provide fuel for exercise. Nucleotides can be obtained from the diet, and produced or salvaged by the body. Though nucleotides provide the building blocks for ATP, the sugar ribose has been suggested to be rate limiting for synthesising ATP.

Previous studies have shown a decrease in ATP levels in the muscle after intense exercise, and this is linked to fatigue. Other studies have also reported benefits of nucleotide and/or ribose supplementation on exercise performance. However, any potential link between ATP metabolism and exercise performance has not been explored.

This study will look at the effects of nucleotide and nucleotide-ribose supplementation in fuel utilisation and performance in skeletal muscle during endurance exercise.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: Low nucleotide; Dietary supplement: High nucleotide; Dietary supplement: High nucletide + Ribose

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Devon
    • Exeter, Devon, United Kingdom, EX2 4TH
      • University of Exeter - St Luke's Campus

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• BMI between 18 and 30

Exclusion Criteria:

• On medication (except contraception)
• Smokers
• Diagnosed with any metabolic or cardiovascular conditions
• Muscle or bone injuries
• BMI < 18 or > 30

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Low nucleotide; 2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose	Dietary supplement: Low nucleotide; 2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
Experimental: High nucleotide; 2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose	Dietary supplement: High nucleotide; 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
Experimental: High nucletide + Ribose; 2 week supplementation with a high nucleotide mycoprotein drink, with added ribose	Dietary supplement: High nucletide + Ribose; 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Changes in muscle ATP concentrations	After each supplementation cycle (day 15 of each cycle): baseline (fasted and before exercise), immediately after glycogen depleting exercise (after exercising for 1:30 - 2 hours), immediately after 15 minute time trial and after 3-hour recovery

Secondary Outcome Measures

Outcome Measure	Time Frame
Changes in muscle glycogen concentrations	After each supplementation cycle (day 15 of each cycle): baseline (fasted and before exercise), immediately after glycogen depleting exercise (after exercising for 1:30 - 2 hours), immediately after 15 minute time trial and after 3-hour recovery
Blood lactate concentrations	After supplementation cycle (day 15): baseline and at 15 minute intervals up 1 hour during glycogen depleting exercise
Blood glucose concentrations	After supplementation cycle (day 15): baseline and at 15 minute intervals up 1 hour during glycogen depleting exercise
Serum uric acid concentrations	Measured at baseline and of days 6, 8 and 15 of each supplementation cycle

Collaborators and Investigators

• Sponsor: University of Exeter

Study record dates

Study Major Dates

• Study Start (Actual): June 28, 2018
• Primary Completion (Actual): February 2, 2020
• Study Completion (Actual): February 2, 2020

Study Registration Dates

• First Submitted: June 13, 2018
• First Submitted That Met QC Criteria: September 3, 2018
• First Posted (Actual): September 6, 2018

Study Record Updates

• Last Update Posted (Actual): March 26, 2020
• Last Update Submitted That Met QC Criteria: March 25, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 171206/B/04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No